We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a ...

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.67 or 6.36% from the prior close of $10.53. The stock opened at $10.48 and ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

The average one-year price target for Vir Biotechnology (NasdaqGS:VIR) has been revised to 33.08 / share. This is an increase of 9.93% from the prior estimate of 30.09 dated January 16 ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion ...

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...